Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EVT 201: Phase II data

In a double-blind, U.S. Phase II trial in 149 elderly primary insomnia patients with daytime sleepiness, both doses of EVT 201 (1.5

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE